Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.venusremedies.com | |
Market Cap | 304.10 Cr. | |
Enterprise Value(EV) | 292.67 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 19.88 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 11.45 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 33.57 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 344.38 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 0.66 | Calculated using Price: 227.50 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.34 Cr. | 13,366,988 Shares |
FaceValue | 10 | |
About Venus Remedies Ltd. | ||
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics. |
1 Day |
|
+1.25% |
1 Week |
|
-5.29% |
1 Month |
|
+11.17% |
3 Month |
|
+39.44% |
6 Month |
|
+19.14% |
1 Year |
|
+4.24% |
2 Year |
|
-27.97% |
5 Year |
|
+325.63% |
10 Year |
|
-21.50% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 15.38 | 1.12 | 0.38 | -4.13 | -8.18 | -8.23 | -3.05 | 17.40 | 9.85 | |
Return on Capital Employed (%) | 14.06 | 5.74 | 5.35 | 2.00 | 1.17 | -0.67 | 0.90 | 12.37 | 7.89 | |
Return on Assets (%) | 8.29 | 0.62 | 0.20 | -2.12 | -4.05 | -3.85 | -1.45 | 10.30 | 7.18 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
Shh. Funds | 462 | 457 | 438 | 389 | 362 | 333 | 323 | 400 | 440 | 460 | |
Non Curr. Liab. | 162 | 222 | 212 | 180 | 158 | 137 | 96 | 58 | 46 | 58 | |
Curr. Liab. | 211 | 163 | 193 | 197 | 230 | 264 | 225 | 97 | 93 | 83 | |
Minority Int. | |||||||||||
Equity & Liab. | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 579 | 601 | |
Non Curr. Assets | 562 | 608 | 566 | 506 | 491 | 467 | 350 | 322 | 301 | 278 | |
Curr. Assets | 272 | 233 | 277 | 259 | 260 | 265 | 294 | 234 | 278 | 323 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 579 | 601 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. TTM |
Net Sales | 542 | 464 | 418 | 400 | 372 | 322 | 339 | 548 | 599 | 556 | |
Other Income | 0 | 1 | 2 | 4 | 2 | 6 | 5 | 20 | 8 | 10 | |
Total Income | 542 | 465 | 420 | 404 | 375 | 328 | 345 | 568 | 607 | 566 | |
Total Expenditure | -403 | -375 | -337 | -349 | -333 | -289 | -299 | -494 | -537 | -495 | |
PBIDT | 139 | 90 | 83 | 55 | 42 | 39 | 46 | 73 | 70 | 71 | |
Interest | -29 | -41 | -38 | -36 | -36 | -25 | -13 | -13 | 0 | 0 | |
Depreciation | -40 | -46 | -42 | -40 | -34 | -34 | -32 | -35 | -34 | -32 | |
Taxation | -5 | 3 | -2 | 5 | -3 | 1 | -2 | 13 | 4 | -11 | |
Exceptional Items | -9 | -9 | 23 | ||||||||
PAT | 64 | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 64 | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | |
Adjusted EPS | 56 | 5 | 1 | -14 | -25 | -23 | -8 | 50 | 30 | 20 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 52 | 53 | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | |
Cash Fr. Inv. | -104 | -95 | -67 | 3 | -18 | -11 | -11 | -5 | 56 | -17 | |
Cash Fr. Finan. | 55 | 40 | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -9 | |
Net Change | 3 | -2 | -1 | 3 | -4 | -20 | -1 | 0 | 26 | 15 | |
Cash & Cash Eqvt | 6 | 4 | 4 | 7 | 4 | -20 | 3 | 2 | 29 | 43 |
Wed, 07 Jun 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem Oncology Parenteral Facilities. |
Thu, 01 Jun 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Venus Remedies consolidates its position in oncology space with Saudi marketing approval for Docetaxel. |
Wed, 31 May 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Please find enclosed herewith newspaper publication of Financial Results for the quarter and year ended on 31st March 2023. |
Fri, 09 Jun 2023 |
|
S Making Lower Lows for 2 Days |
|
|
|